Evidence map›Paper›PMID 40917892›Full record

ReviewMolecular therapy. Nucleic acids2025

MicroRNAs and synaptic dysfunction in Parkinson's disease.

Morgan N Ogwo, Bhupender Sharma, Gunjan Goyal, Rajkumar Lakshmanaswamy, Subodh Kumar

Abstract readReview
In one paragraph

Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Fully Automated Azeotropic Drying-Free Synthesis of [Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Morgan N OgwoCenter of Emphasis in Neuroscience, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Bhupender SharmaCenter of Emphasis in Neuroscience, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Gunjan GoyalCenter of Emphasis in Neuroscience, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Rajkumar LakshmanaswamyCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Subodh KumarCenter of Emphasis in Neuroscience, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a debilitating neurodegenerative condition. Synaptic dysfunctions are associated with the onset and progressive neurodegeneration exhibited in PD. Healthy, active synapses are a prerequisite for non-pathological neurotransmission. When neurotransmission becomes pathological, such as observed in neurodegenerative conditions like PD, the biomolecules found in and around such synapses need distinctive investigation. MicroRNAs (miRNAs) found in neuronal subcellular compartments, such as dendrites, pre-synaptic boutons, and synaptic vesicles, have been garnering attention in neurogenerative diseases. MiRNAs that modulate synaptic activity and synapse function are called synaptic miRNAs. Several miRNAs have been identified that regulate key synaptic proteins; however, information about synaptic miRNAs is largely unknown in PD. In this review, we focused on the most promising synaptic miRNAs, those that are critical for normal synapse function and play a crucial role in PD pathology. We also discussed the synaptic miRNA's interplay with PD-associated synaptic dysfunction. Investigating further how synaptic miRNAs impacts PD pathogenesis may uncover novel etiological information and potential pathways for treatments and a cure for PD.

Indexed as

Alpha-synucleinCerebral cortexDopaminergicMicroRNAsMT: Non-coding RNAsParkinson’s diseaseStriatumSubstantia nigraSynapseSynaptic plasticity

Identifiers

PMID40917892
PMCPMC12408229

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.